Pharma Stock Plummets on Skin Disease Trial - Schaeffer's Investment Research
Acelyrin Inc's stock (NASDAQ:SLRN) drops 62% to $10.60 after its skin disease drug fails in a trial. Jefferies cuts price target to $15 from $31, calling the data 'painfully disappointing.' Despite a 'strong buy' rating from analysts, SLRN faces volatility and lands on the short sell restricted list.
Reference News
Pharma Stock Plummets on Skin Disease Trial - Schaeffer's Investment Research
Acelyrin Inc's stock (NASDAQ:SLRN) drops 62% to $10.60 after its skin disease drug fails in a trial. Jefferies cuts price target to $15 from $31, calling the data 'painfully disappointing.' Despite a 'strong buy' rating from analysts, SLRN faces volatility and lands on the short sell restricted list.